Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
出版年份 2023 全文链接
标题
Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
作者
关键词
-
出版物
JOURNAL OF IMMUNOTHERAPY
Volume 46, Issue 2, Pages 64-73
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-01-14
DOI
10.1097/cji.0000000000000451
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
- (2022) Jianqiong Yin et al. Frontiers in Immunology
- Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer
- (2022) Haitao Tao et al. Translational Lung Cancer Research
- Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
- (2022) Yencheng Chao et al. Translational Lung Cancer Research
- The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
- (2021) Mizuho Asada et al. ONCOLOGY
- Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina
- (2021) William T. Atchley et al. CHEST
- Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
- (2021) Aiben Huang et al. BMC CANCER
- Imaging Features of Pulmonary Immune-related Adverse Events
- (2021) Chiara Pozzessere et al. Journal of Thoracic Oncology
- Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
- (2021) Kang Miao et al. Thoracic Cancer
- Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
- (2021) Kana Ono et al. Cancer Medicine
- Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
- (2021) Xinqing Lin et al. Frontiers in Oncology
- Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non–Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis
- (2021) Yanlin Li et al. Clinical Lung Cancer
- Dynamic changes in the radiologic manifestation of a recurrent checkpoint inhibitor related pneumonitis in a non-small cell lung cancer patient: A case report
- (2021) Pei-Xin Tan et al. World Journal of Clinical Cases
- Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report
- (2020) Hirofumi Utsumi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer
- (2020) Mingjia Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chronic immune checkpoint inhibitor pneumonitis
- (2020) Jarushka Naidoo et al. Journal for ImmunoTherapy of Cancer
- Tumor invasion in the central airway is a risk factor for early‐onset checkpoint inhibitor pneumonitis in patients with non‐small cell lung cancer
- (2020) Mitsuhiro Moda et al. Thoracic Cancer
- Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
- (2020) Xiangling Chu et al. LUNG CANCER
- Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
- (2020) Hanping Wang et al. Cancer Medicine
- Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors
- (2019) Nethanel Asher et al. ONCOLOGIST
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer
- (2019) Mari Tone et al. Thoracic Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started